Takeda acquires Millennium

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=ir

By | April 10, 2008

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1127852&highlight= by Takeda Pharmaceuticals, Japan's largest pharma company, for a whopping $8.8 billion dollars. Although Millennium will become a wholly owned subsidiary, the company will continue its operations in Cambridge Massachusetts.

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Record-Setting Corn Grows 45 Feet Tall
AAAS